Loading...
PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study
OBJECTIVE: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other vascular cells by targeting the intracellular surface...
Na minha lista:
| Udgivet i: | Arterioscler Thromb Vasc Biol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Lippincott Williams & Wilkins
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7682800/ https://ncbi.nlm.nih.gov/pubmed/33028101 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.120.315168 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|